Formulation makes water soluble cannabidiol (CBD) oil up to 40 times better absorbed
Australia based Holista CollTech announced that it has filed its 100%-owned global patent for platform technology that will deliver many fat-soluble medications by creating a water-soluble delivery system. This patented process can apply to a whole range of molecules including the Cannabidiol (CBD) oil industry.
The patent was registered in the USA and filed for a global coverage, as US Filing No: 16/694,197 (the patent may be viewed on the Holista website). Holista has instructed its patenting firm to secure all global strategic markets world-wide. With the patent filing completed, Holista has commenced negotiations with companies involved in CBD processing in North America and expect these negotiations to complete in 2020,
In a statement released this week, by Project Leader and head of Holista’s Technical Advisory Panel, Dr Roscoe Moore Jr stated “Working on developing this technology is exciting. Most medicine consumed orally is wasted due to its poor absorption by the body. This is especially true for CBD, which is also expensive. More important, the integrity of the final molecule is preserved exactly as it is found in nature and hence, there is no apparent need for any lengthy approvals process anywhere in the world. We only use materials certified as ’Generally Regarded as Safe’ (GRAS) by the FDA.”
The commercial benefits for the CBD producers include making their CBD formulation up to 40 times more potent (allowing them to reduce their dosages significantly) as well as making their product palatable for the young and the elderly.Fat-soluble molecules have poor bioavailability as they don’t dissolve well and reach the bloodstream. As such, a higher dosage needs to be ingested. This is both wasteful and costly. The platform technology will particularly benefit the Cannabidiol (CBD) oil industry where the active material is scarce, costly and poorly water-soluble. Holista is focused on fat-soluble substances such as CBD, curcumin and Vitamin D, targeting initially the food and nutraceutical markets in Australia and North America.